Charles O’Neill

Also affiliated with Q Therapeutics (United States), Mayo Clinic Hospital, BioMarin (United States)

MedicineBiochemistry, Genetics and Molecular BiologyBusiness, Management and Accounting

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB”.

Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB

Journal of Pharmacology and Experimental Therapeutics(2022)10.1124/jpet.122.001119

N/A

0.339DataRank · unranked

7 citations

Bethann Valentine, Andrew S. Hess, Jackie K. Jens, Elizabeth Snella, Maryam Jamil +32 more

Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis

Experimental Eye Research(2020)10.1016/j.exer.2020.108130

N/A

0DataRank · unranked

20 citations

Jacqueline W. Pearce, Daniella P. Vansteenkiste, Katherine Bibi, Stefanie Lim, Grace Robinson Kick +7 more

Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis

Experimental Eye Research(2020)10.1016/j.exer.2020.108135

N/A

0DataRank · unranked

19 citations

Grace Robinson Kick, Juri Ota‐Kuroki, Stefanie Lim, Leilani J. Castaner, Cheryl A. Jensen +6 more